American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SANTA MONICA, Calif., Feb. 24, 2016 -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that it will report fourth quarter and full year 2015 financial results on Monday, February 29, 2016 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 PM Eastern Time (1:30 PM Pacific Time).
Audio Webcast
Interested parties may access a live audio webcast of the conference call on the Investors section of Kite’s website, www.kitepharma.com. A replay of the webcast will be available on the website for approximately 30 days.
Dial-In Information
Live (U.S. / Canada): (877) 301-8565
Live (International): (678) 562-4240
Confirmation number: 45173015
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
CONTACT: Greg Mann VP, Investor Relations [email protected] For Media: Justin Jackson Burns McClellan (212) 213-0006 [email protected]
